<DOC>
	<DOCNO>NCT01876433</DOCNO>
	<brief_summary>Objective : The objective study assess structural functional cardiac effect treatment beta 3 AR agonist Mirabegron patient chronic heart failure . Design : We plan study aim establish proof concept treatment patient HF Mirabegron significant positive effect , assess clinical biochemistry measurement , hard endpoint . We perform combine dose-finding - chronic efficacy study . The study randomize , placebo‐controlled , double‐blinded trial . The follow‐up period 6 month . 70 patient chronic heartfailure include . Specific aim 1 . Determine safety administration Mirabegron patient heart failure . 2 . Determine treatment Mirabegron 6 month induces beneficial cardiac structural remodelling patient heart failure . 3 . Determine Mirabegron improve symptom exercise capacity indicate questionnaire 6 min walk test patient heart failure . 4 . Determine effect Mirabegron cardiac conduction , repolarisation rhythm arrhythmia patient heart failure . 5 . Determine effect Mirabegron circulate biomarkers patient heart failure .</brief_summary>
	<brief_title>Beta 3 Agonist Treatment Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>1 . Stable heart failure NYHA class IIIII ischemic nonischemic basis 2 . Left ventricular ejection fraction ( LVEF ) &lt; 40 % 3 . Stable sinus rhythm ( SR ) 4 . On optimised evidencebased pharmacological HF treatment stable &gt; 4 week current plan change HF therapy . The therapy must include betablocker . 5 . No change diuretic &lt; 4 week 6 . &gt; 18 year 1 . Unstable cardiac condition 2 . Acute myocardial infarction ( AMI ) revascularisation &lt; 3 month ago 3 . Atrial fibrillation ( technical reason relation image HR reporting ) 4 . Uncorrected significant primary obstructive valve disease 5 . Planned major surgery include cardiac revascularisation 6 . Hemodynamically significant obstructive cardiomyopathy 7 . Stroke significant neurological deficit 8 . Acute myocarditis constrictive pericarditis 9 . Symptomatic bradycardia &gt; 1. degree AVblock unless patient pacemaker 10 . Clinically significant hepatic ( transaminase bilirubin x 3 upper reference level ) renal ( GFR &lt; 50 ml/min/1,73 m2 ) diseases 11 . Heart failure due uncorrected thyroid disease 12 . Cardiac mechanical support 13 . &lt; 6 month CRT 14 . Uncontrolled hypotension ( define symptomatic systolic blood pressure &lt; 90 mmHg ) hypertension ( define systolic 180 mmHg and/or diastolic blood pressure 110 mmHg ) 15 . Body mass index ( BMI ) &gt; 35 16 . Unable give inform consent 17 . Reduced compliance 18 . All woman child bear potential require use adequate contraception 19 . Pregnant lactate woman 20 . Treatment tricyclic antidepressant CYP2D6 substrates betablockers treatment digoxin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>